This pathway is widely dysregulated in a variety of human cancers, including haematological malignancies, breast cancer and colorectal cancer, illustrating the potential value of developing PI3K inhibitors (De Santis et al. 2019). The gene discussed is PIK3CG; the disease is cancer.